Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

$24.99

Analysis of Profitability Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Profitability Ratios (Summary)

Regeneron Pharmaceuticals Inc., profitability ratios (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Return on Sales
Gross profit margin
Operating profit margin
Net profit margin
Return on Investment
Return on equity (ROE)
Return on assets (ROA)

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The profitability metrics exhibited varied trends over the observed period. Generally, a decline in operating performance is apparent, while net profitability demonstrated more fluctuation and a late-period recovery. Return on equity and return on assets both showed consistent declines, though stabilized in the most recent quarters.

Gross Profit Margin
The gross profit margin remained consistently high throughout the period, fluctuating within a relatively narrow range of approximately 84.65% to 87.18%. A slight upward trend was observed from March 2022 to December 2022, followed by a gradual decline through December 2025, ending at 85.35%. This suggests consistent cost of goods sold management despite broader profitability shifts.
Operating Profit Margin
A clear downward trend is evident in the operating profit margin. Starting at 55.08% in March 2022, it decreased steadily to 24.95% by December 2025. The most significant declines occurred between March 2022 and December 2022, and again between September 2023 and December 2025. This indicates increasing operating expenses relative to revenue.
Net Profit Margin
The net profit margin experienced more volatility than the gross or operating margins. It declined from 48.06% in March 2022 to 30.14% in December 2022, before showing some recovery, peaking at 33.61% in September 2024. However, it subsequently decreased to 31.41% by December 2025. This suggests that factors beyond core operations, such as taxes or non-operating income/expenses, significantly impacted net income.
Return on Equity (ROE)
Return on equity demonstrated a consistent decline from 39.84% in March 2022 to 14.41% in December 2025. The rate of decline slowed in the later quarters, suggesting a potential stabilization. This decrease likely reflects the declining net income and potentially changes in equity structure.
Return on Assets (ROA)
Similar to ROE, return on assets exhibited a downward trend, decreasing from 30.11% in March 2022 to 11.11% in December 2025. The decline mirrored that of ROE, indicating that the company generated less profit from its assets over time. The rate of decline also slowed towards the end of the period.

In summary, while the company maintained a strong gross profit margin, its operating and net profitability experienced declines. The returns on equity and assets followed suit, indicating a diminishing ability to generate profits from both shareholder investments and total assets. The stabilization observed in the most recent quarters warrants further investigation to determine if this represents a turning point or a temporary pause in the downward trends.


Return on Sales


Return on Investment


Gross Profit Margin

Regeneron Pharmaceuticals Inc., gross profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Gross profit
Revenues
Profitability Ratio
Gross profit margin1
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Gross profit margin = 100 × (Gross profitQ4 2025 + Gross profitQ3 2025 + Gross profitQ2 2025 + Gross profitQ1 2025) ÷ (RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The gross profit margin exhibited relative stability over the observed period, generally fluctuating within a narrow range. Initial values demonstrate a strong margin, with a slight upward trend observed through the end of 2022. Subsequent periods show a leveling off, followed by a modest decline, and then a slight recovery towards the end of the period.

Overall Trend
The gross profit margin began at 84.65% in March 2022 and concluded at 85.35% in December 2025. The highest recorded margin was 87.18% in December 2022, while the lowest was 84.65% in March 2022 and 85.39% in September 2025.
2022 Performance
Throughout 2022, the gross profit margin demonstrated a consistent, albeit gradual, increase. Starting at 84.65% in March, it rose to 84.97% in June, 85.39% in September, and peaked at 87.18% in December. This suggests improving cost management or pricing power during this timeframe.
2023 Fluctuations
The gross profit margin in 2023 experienced more fluctuation. It began at 86.96% in March, decreased to 86.42% in June, then increased to 85.96% in September, and slightly decreased to 86.16% in December. This indicates a period of less consistent performance compared to the prior year.
2024 and 2025 Developments
In 2024, the gross profit margin remained relatively stable, hovering around 86.1% to 86.3%. A slight decline was observed in early 2025, falling to 85.79% in March and 85.57% in June, before recovering to 85.39% in September and 85.35% in December. This suggests potential cost pressures or pricing adjustments that were partially offset later in the year.

The observed patterns suggest a generally healthy gross profit margin, with some degree of sensitivity to external factors or internal operational changes. The slight decline in the latter periods warrants continued monitoring to assess its sustainability and potential impact on overall profitability.


Operating Profit Margin

Regeneron Pharmaceuticals Inc., operating profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Income from operations
Revenues
Profitability Ratio
Operating profit margin1
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Operating profit margin = 100 × (Income from operationsQ4 2025 + Income from operationsQ3 2025 + Income from operationsQ2 2025 + Income from operationsQ1 2025) ÷ (RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The operating profit margin exhibited a consistent downward trend over the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the margin stood at 55.08% but progressively declined to 24.95% by the end of the period. While fluctuations occurred within this overall trend, the direction remained consistently negative.

Initial Phase (Mar 31, 2022 – Dec 31, 2022)
The operating profit margin experienced a substantial decrease from 55.08% to 38.93% during this timeframe. This represents a significant contraction, suggesting increasing costs relative to revenue or pricing pressures. The largest single-quarter decline occurred between March and June 2022.
Stabilization and Further Decline (Mar 31, 2023 – Dec 31, 2024)
The rate of decline appeared to moderate slightly between March 2023 and December 2024, with the margin decreasing from 35.79% to 28.10%. However, the trend remained downward. Revenue growth during this period did not fully offset the pressures on profitability.
Recent Period (Mar 31, 2025 – Dec 31, 2025)
The final observed period showed a continuation of the declining trend, with the operating profit margin falling from 27.20% to 24.95%. This suggests that the factors contributing to the margin compression persisted and potentially intensified.

Income from operations also demonstrated variability, but the consistent decline in the operating profit margin indicates that revenue growth was insufficient to maintain profitability levels. The observed pattern suggests a need for further investigation into cost structures, pricing strategies, and competitive pressures impacting the business.

Revenue Correlation
While revenues generally increased over the period, the operating profit margin’s decline suggests that the cost of generating those revenues increased at a faster rate. A detailed analysis of cost of goods sold and operating expenses would be necessary to pinpoint the specific drivers of this trend.

Net Profit Margin

Regeneron Pharmaceuticals Inc., net profit margin calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Net income
Revenues
Profitability Ratio
Net profit margin1
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Net profit margin = 100 × (Net incomeQ4 2025 + Net incomeQ3 2025 + Net incomeQ2 2025 + Net incomeQ1 2025) ÷ (RevenuesQ4 2025 + RevenuesQ3 2025 + RevenuesQ2 2025 + RevenuesQ1 2025)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The net profit margin exhibited fluctuations over the observed period, generally trending downwards before stabilizing and showing some recovery. Initial values were relatively high, but a consistent decline was apparent through 2022 and into the first half of 2023. The latter half of 2023 and 2024 saw some volatility, with a slight upward movement followed by a decrease, before showing a modest increase again in the most recent quarters.

Overall Trend
From March 2022 to September 2023, the net profit margin decreased from 48.06% to 30.47%. This represents a substantial reduction in profitability relative to revenue. Following this decline, the margin experienced fluctuations, ultimately reaching 31.41% by December 2025, indicating a partial recovery but not a return to the initial levels.
2022 Performance
The net profit margin began at 48.06% in March 2022, demonstrating strong profitability. However, a consistent downward trend was observed throughout the year, ending at 35.64% in December 2022. This suggests increasing costs or decreasing revenue, or a combination of both, impacting profitability.
2023 Volatility
2023 showed increased volatility. The margin started at 33.81% in March, rose to 33.93% in June, then decreased to 30.47% in September, and recovered slightly to 30.14% by December. This suggests potential seasonal effects or the impact of specific business events on profitability during the year.
Recent Performance (2024-2025)
The net profit margin continued to fluctuate in 2024, reaching a high of 33.61% in September before decreasing to 31.07% in December. The trend continued into 2025, with a slight increase to 32.13% in September and a final value of 31.41% in December. This indicates a period of stabilization, albeit at a lower level than the initial values observed in 2022.

The observed patterns suggest that while the company maintains profitability, its ability to convert revenue into profit has been challenged. Further investigation into the underlying drivers of revenue and cost changes would be necessary to fully understand these trends.


Return on Equity (ROE)

Regeneron Pharmaceuticals Inc., ROE calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Net income
Stockholders’ equity
Profitability Ratio
ROE1
Benchmarks
ROE, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
ROE = 100 × (Net incomeQ4 2025 + Net incomeQ3 2025 + Net incomeQ2 2025 + Net incomeQ1 2025) ÷ Stockholders’ equity
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The Return on Equity (ROE) for the analyzed period demonstrates a clear declining trend, followed by a period of relative stabilization and a recent slight increase. Initial values are notably high, but consistently decrease over the first several quarters before leveling off and showing a minor upward movement towards the end of the observed timeframe.

Overall Trend
ROE begins at 39.84% in March 2022 and experiences a substantial decrease to 19.14% by December 2022. This represents a significant contraction in profitability relative to equity. From December 2022 through December 2024, the ROE fluctuates within a narrow range, generally between 14.29% and 15.87%, indicating a period of stabilization. The most recent quarters show a slight increase, reaching 14.89% in June 2025 and 14.41% in December 2025.
Initial Decline (Mar 31, 2022 – Dec 31, 2022)
The most pronounced decrease in ROE occurs within the first year of the period. This decline coincides with fluctuations in net income, which, while remaining substantial, exhibits variability. Simultaneously, stockholders’ equity consistently increases, contributing to the reduction in ROE as the denominator grows at a faster rate than the numerator.
Stabilization Period (Jan 1, 2023 – Dec 31, 2024)
Following the initial decline, ROE enters a period of relative stability. Net income demonstrates more consistent performance, and the rate of growth in stockholders’ equity slows. This suggests a balancing effect between profitability and equity expansion, resulting in a more consistent ROE.
Recent Fluctuations (Jan 1, 2025 – Dec 31, 2025)
The final quarters show a slight upward trend in ROE, although the values remain within the stabilized range observed previously. Net income experiences a notable increase in June 2025, contributing to this slight improvement. Stockholders’ equity continues to grow, but at a rate that allows for a modest increase in ROE.

In summary, the ROE trajectory indicates an initial period of significant decline, followed by stabilization, and a recent, minor recovery. The interplay between net income and stockholders’ equity is a key driver of these observed changes.


Return on Assets (ROA)

Regeneron Pharmaceuticals Inc., ROA calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in thousands)
Net income
Total assets
Profitability Ratio
ROA1
Benchmarks
ROA, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
ROA = 100 × (Net incomeQ4 2025 + Net incomeQ3 2025 + Net incomeQ2 2025 + Net incomeQ1 2025) ÷ Total assets
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The Return on Assets (ROA) exhibited a declining trend over the observed period, beginning with a relatively high value and gradually decreasing. Initial values demonstrate substantial profitability relative to the asset base, but subsequent quarters reveal a moderation of this performance.

Initial Performance (Mar 31, 2022 - Dec 31, 2022)
The ROA commenced at 30.11% in March 2022, indicating a strong ability to generate earnings from its assets. A noticeable decline followed, reaching 20.90% in June 2022, 19.40% in September 2022, and further decreasing to 14.85% by December 2022. This represents a significant reduction within a short timeframe, suggesting potential shifts in operational efficiency or asset utilization.
Stabilization and Fluctuations (Mar 31, 2023 - Dec 31, 2023)
From March 2023 through December 2023, the ROA experienced a period of relative stabilization, fluctuating between 11.95% and 14.02%. While not exhibiting the steep decline of the previous period, the values remained consistently lower than those observed in the earlier part of 2022. This suggests that the factors contributing to the initial decline persisted, preventing a substantial recovery.
Recent Trends (Mar 31, 2024 - Dec 31, 2025)
The ROA demonstrated minor fluctuations between 11.11% and 12.43% over the most recent period. A slight increase is observed in June 2024 (11.98%) and September 2024 (12.43%), but this is followed by a return to lower values. The final reported ROA for December 2025 is 11.11%, representing the lowest value in the observed timeframe. This indicates a continued, albeit gradual, erosion of profitability relative to the asset base.

Overall, the ROA trend suggests a weakening in the company’s ability to generate profits from its assets. While fluctuations occur, the general direction is downward, warranting further investigation into the underlying drivers of this trend, such as changes in net income, asset efficiency, or asset composition.